Related Experiment Video
Updated: Jul 5, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Non-invasive testing and risk-stratification in patients with MASLD
Mirko Zoncapè1, Antonio Liguori2, Emmanuel A Tsochatzis3
1Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK; UCL Institute for Liver and Digestive Health, University College London, UK; Liver Unit, Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
Non-invasive fibrosis tests (NITs) are revolutionizing hepatology for Metabolic Associated Steatotic Liver Disease (MASLD). These tests aid in diagnosing and staging liver conditions, improving patient outcomes and risk assessment.
Area of Science:
- Hepatology
- Gastroenterology
- Diagnostic Medicine
Background:
- Metabolic Associated Steatotic Liver Disease (MASLD), previously NAFLD, is highly prevalent in Western populations.
- Accurate diagnosis and staging of MASLD are crucial for effective patient management.
- Non-invasive fibrosis tests (NITs) have emerged as key tools in hepatology practice.
Purpose of the Study:
- To review the current applications of NITs in the diagnosis and staging of MASLD.
- To critically evaluate recent data on the efficacy of various NITs for MASLD.
- To highlight the prognostic value of NITs in predicting liver-related outcomes.
Main Methods:
- Review of serum markers (e.g., FIB-4, pro-C3, ELF).
- Evaluation of imaging techniques (e.g., Fibroscan®, MRE).
- Analysis of combined scoring systems (e.g., Agile 3+, Agile 4).
Main Results:
- NITs offer diverse options for diagnosing steatosis, steatohepatitis, and fibrosis in MASLD.
- Recently published data support the utility of these non-invasive approaches.
- NITs demonstrate significant value in prognostic assessment for MASLD patients.
Conclusions:
- NITs have significantly advanced the clinical management of MASLD.
- A range of NITs are available for diagnosing and staging liver disease.
- These tests are essential for risk stratification and improving patient prognosis in MASLD.
More Related Videos
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018